Table 1.
Age, years | Sex | BMI | Pack years | FEV1 (l) | FEV1 (% pred) | FEV1/FVC | Reversibility (ml) (<200 ml) | Regular β2-agonists | |
---|---|---|---|---|---|---|---|---|---|
1 | 72 | M | 37 | 42 | 0.75 | 25 | 44 | 50 | F, Sb |
2 | 75 | F | 35 | 60 | 1.05 | 58 | 62 | 0 | Sb |
3 | 54 | F | 28 | 26 | 1.4 | 51 | 54 | 160 | Sm, Sb |
4 | 59 | M | 26 | 60 | 1.64 | 48 | 52 | 60 | Sm, Sb |
5 | 75 | F | 23 | 41 | 0.88 | 49 | 53 | 150 | Sb |
6 | 67 | M | 20 | 10 | 0.5 | 18 | 28 | 20 | Sb |
7 | 71 | M | 21 | 69 | 0.74 | 30 | 44 | 60 | Sb |
8 | 62 | F | 20 | 40 | 1.22 | 53 | 53 | 0 | F, Sb |
9 | 77 | M | 56 | 27 | 0.82 | 31 | 32 | 160 | Sm, Sb |
10 | 71 | M | 33 | 0 | 0.95 | 51 | 51 | 150 | Sb |
11 | 66 | M | 21 | 25 | 1.4 | 44 | 49 | 0 | Sm, Sb |
12 | 64 | M | 28 | 48 | 1.95 | 56 | 65 | 0 | F,T |
13 | 63 | F | 19 | 60 | 0.95 | 41 | 44 | 70 | Sm, Sb |
14 | 60 | M | 22 | 45 | 2.65 | 69 | 63 | 140 | |
15 | 62 | F | 34 | 30 | 1.37 | 59 | 58 | 100 | Sm,Sb |
16 | 60 | M | 21 | 56 | 0.75 | 23 | 25 | 50 | F, Sb |
17 | 77 | M | 28 | 0 | 1.4 | 55 | 50 | 120 | Sm, T |
18 | 75 | M | 22 | 50 | 1.28 | 42 | 49 | 80 | Sm |
19 | 52 | M | 29 | 24 | 2.52 | 68 | 53 | 0 | T |
20 | 67 | M | 28 | 75 | 2.11 | 63 | 54 | 0 | Sm |
F, Formoterol; Sb, Salbutamol; Sm, Salmeterol; T, Terbutaline; BMI, body mass index, FEV1, forced expiratory volume in 1 s.